As-Needed Albuterol-Budesonide in Mild Asthma.

Summary

In this double-blind, event-driven phase 3b trial (n=2,516), as-needed albuterol–budesonide reduced severe exacerbations by about half versus albuterol alone in mild asthma, with similar adverse events and lower systemic steroid exposure. The trial stopped early for efficacy at interim analysis.

Key Findings

• Severe exacerbations: 5.1% with albuterol–budesonide vs 9.1% with albuterol alone (on-treatment; HR 0.53; 95% CI 0.39–0.73; P<0.001).
• Intention-to-treat analysis: 5.3% vs 9.4% (HR 0.54; 95% CI 0.40–0.73; P<0.001).
• Annualized severe exacerbation rate reduced (0.15 vs 0.32; rate ratio 0.47; 95% CI 0.34–0.64).
• Lower mean annual systemic glucocorticoid dose (23.2 vs 61.9 mg/year).
• Adverse events were similar between groups.

Clinical Implications

Clinicians can consider as-needed albuterol–budesonide instead of SABA-only for mild asthma to reduce severe exacerbations and systemic steroid exposure.

Limitations

• Fully virtual, decentralized design may affect generalizability and adherence assessment.
• Trial stopped early for efficacy, which can overestimate effect sizes.

Future Directions

Head-to-head comparisons with maintenance low-dose ICS, real-world effectiveness across diverse health systems, and long-term safety are warranted.